tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

AstraZeneca raises FY22 core EPS view to high 20s to low 30s percentage

Previous view was mid to high 20s percentage. The company backed its FY22 revenue view of up by a low 20s percentage. At actual exchange rates, it is anticipated that FY 2022 Total Revenue growth will also be impacted by a currency headwind of a mid single-digit percentage, and that FY 2022 Core EPS growth will be impacted by a currency headwind of a mid-to-high single-digit percentage.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on AZN:

Disclaimer & DisclosureReport an Issue

1